tdoctoral fellowship in Production and Operations Management at the Harvard Business School. He is fluent in Japanese and has lived and worked in Japan for seven years. He received two Fulbright Fellowships and a Japan Foundation Fellowship for studying at Tokyo University. He has been a visiting professor at Hitotsubashi University and Tokyo University in Japan, Imperial College in London, the University of St. Gallen in Switzerland, the University of Maryland, and Ludwig Maximilians University in Munich.
Dr. Cusumano has consulted for some 90 companies around the world, including Alcatel, Amadeus, AOL, AT&T, BMC Software, Business Objects, Cisco, Ericsson, Fiat, Ford, Fujitsu, General Electric, Fidelity, Verizon, Hitachi, Huawei, i2 Technologies, IBM, Intel, Lucent, Motorola, NASA, NEC, Nokia, Nortel, NTT Data, Philips, Robert Bosch, Schlumberger, Siemens, Texas Instruments, and Toshiba. He has been a director of several public and private companies, including Patni Computer Systems (www.patni.com, an IT services firm sold to iGate-Apax in 2011 for $1.2 billion) as well as Eliza Corporation (www.elizacorp.com, a communications and voice-recognition solutions firm sold to Summit Partners in 2011). He is a currently a director of Fusion Storm Global (www.fusionstormglobal.com, an IT solutions provider). He is also on the advisory board of Fixstars Corp. (www.fixstars.com, a developer of high-performance computing applications), and several other companies and organizations. He has also served as editor-in-chief and chairman of the MIT Sloan Management Review and writes a column on Technology Strategy and Management for Communications of the ACM. He was named one of the most influential people in technology and IT by Silicon.com in 2009.
Professor Cusu
'/>"/>
SOURCE Quantum Leap Innovations Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer2.
NeuroCog Trials Appoints Industry Executive Michael Hufford, Ph.D. to Chief Operating Officer3.
Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board4.
Netsmart Technologies Names Michael Valentine as Chief Executive Officer5.
BioNeutral Appoints Michael D. Francis, J.D. as Director to the Board6.
Michael J. Fox Foundation Awards Grant to Zymes LLC7.
Dr. Michael Hanley Joins Celtaxsys as CEO8.
NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of a New Dermal Patch for Parkinsons Disease9.
Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO10.
Michael J. Fox Foundation Launches Parkinsons Progression Markers Initiative (PPMI)11.
Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation